Drug
Cediranib clinical trials
Also written AZD2171 and Recentin.
- studies test it
- 93
- open now
- 2
- in phase 3
- 10
- first study started
- 2003
Keep track of what changes. Save the cediranib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Recentin
- 55
Combined with it in one product
Studies by the year they started
93 studies that test it; most in 2006 (16)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 12 |
| 2006 | 16 |
| 2007 | 9 |
| 2008 | 9 |
| 2009 | 5 |
| 2010 | 10 |
| 2011 | 4 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 29
- Phase 2
- 62
- Phase 3
- 10
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 65
National Cancer Institute (NCI) (44) · AstraZeneca (28) · University Health Network, Toronto (3) · NCIC Clinical Trials Group (2) · University College, London (2) · The Clatterbridge Cancer Centre NHS Foundation Trust (1) · Prof Gordon Jayson (1) · Mario Negri Institute for Pharmacological Research (1)
Often tested with
Tested in the same studies.
Olaparib (19) · Durvalumab (4) · Bevacizumab (2) · AZD 6244 (2) · Ceralasertib (2) · Paclitaxel (2) · Capivasertib (1) · Selumetinib sulfate (1)
Studies
Open first, then newest update. How each study uses cediranib is read from its arms, and is right about nine times in ten.
Testing it · 93
- WIRE - Novel Treatments in Renal Cell CancerRecruitingPhase 2CCTU- Cancer ThemeNCT03741426Written as Cediranib
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04090567Written as Cediranib
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03660826Written as Cediranib Maleate
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01064648Written as Cediranib Maleate
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04739800Written as Cediranib Maleate
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingPhase 1/2National Cancer Institute (NCI)NCT02484404Written as Cediranib
- Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingPhase 2University Health Network, TorontoNCT03851614Written as Cediranib
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT02502266Written as Cediranib
- Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02446600Written as Cediranib Maleate
- Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02345265Written as Cediranib Maleate
- A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02498613Written as Cediranib Maleate
- Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02974621Written as Cediranib
- Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid MalignanciesActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01364051Written as Cediranib
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursActive, not recruitingPhase 1AstraZenecaNCT00750841Written as cediranib
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02893917Written as Cediranib
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01116648Written as Cediranib Maleate
- Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian CancerCompletedPhase 2Prof Gordon JaysonNCT07648745Written as Cediranib
- Sunitinib or Cediranib for Alveolar Soft Part SarcomaCompletedPhase 2National Cancer Institute (NCI)NCT01391962Written as Cediranib
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingPhase 2AstraZenecaNCT03334617Written as Cediranib
- Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaCompletedPhase 2National Cancer Institute (NCI)NCT00942877Written as AZD2171
See all 93 studies that test cediranib →
Given in every arm · 9 — cediranib is usual care beside what is tested
- AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)CompletedPhase 1NCIC Clinical Trials GroupNCT00107250Written as cediranib maleate
- Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian CancerCompletedEarly Phase 1The Christie NHS Foundation TrustNCT02855697Written as Cediranib
- Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01208051Written as Cediranib
- AZD2171 and Temsirolimus in Patients With Advanced Gynecological MalignanciesCompletedPhase 1Susana M. Campos, MDNCT01065662Written as cediranib
- Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With DocetaxelCompletedPhase 2National Cancer Institute (NCI)NCT01260688Written as cediranib maleate
- Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedPhase 2University College, LondonNCT01310855Written as cediranib maleate
- Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00326599Written as cediranib maleate
- Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer PatientsCompletedPhase 1AstraZenecaNCT00960349Written as Cediranib
- Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedPhase 1AstraZenecaNCT00475956Written as AZD2171
Codes
What other systems call cediranib · ClinicalTrials.gg INT004786
- MeSH (NLM) C500926cediranibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) NQU9IPY4K9CEDIRANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q5057052cediranibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80867CediranibOne source FDA
- DrugBank DB04849One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C500926 | cediranib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | NQU9IPY4K9 | CEDIRANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5057052 | cediranib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80867 | Cediranib | One source FDA |
| DrugBank | DB04849 | — | One source Wikidata |
Also registered as cediranib maleate (UNII 68AYS9A614).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.